Performance findings varied across fatigue, escalation and environmental experiments. Higher activation at higher exposure was accompanied by worse accuracy; the program does not show universal performance improvement.
More reported outcomes
Activation versus accuracy
Higher exposure increased errors despite subjective activationNumerical error totals not in the previously checked source notes
Environmental experiments
Cold, heat and simulated altitude tested separatelyDo not sum or merge their denominators
Study notes · methods, sources and limitations
Participants or model Healthy-volunteer fatigue, operator and environmental experiments
Design Separate experiments within the Elistratov dissertation program, not one combined trial.
Important limitations
The activation–accuracy trade-off matters. Small groups, repeated testing and historical controls limit interpretation; the original thesis and complete tables remain missing.
Previously checked dissertation-transcription sections; original full tables are deferred. These experiments are not independent replications.
An experimental multi-ingredient formulation from Russian performance research, built around Bemitil and Trekrezan. It is not a single molecule and is distinct from Binavit.
An experimental Bemitil/Trekrezan formulation with B2/B3 cofactors from the Kirov adaptation program. Fatigue, operator and environmental findings are documented in a dissertation transcription and institutional history.
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
Small healthy-volunteer comparisons across several experimental settings
Study methods
Repeated testing and historical controls; full allocation appraisal pending
Independent replication
Institutional retrospective reuses the original program; independent replication not established
Source access
Russian dissertation transcription and publisher institutional history
Safety evidence
Higher activation accompanied worse accuracy at higher exposure; field and long-term safety unestablished
Open a topic for the evidence assessment.
More findings, background and history
What remains unclear
The Elistratov and Ganapolsky dissertations would clarify how the experimental preparations relate to later commercial proposals. Reviews may repeat cohorts from the original studies.
Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.
Mental-fatigue, escalation and environmental tests are listed separately below. A transcription and later institutional history do not constitute independent replication.
What remains unresolved
Recover the original Elistratov thesis, allocation details, complete tables and safety follow-up.
Small groups; arm-by-environment denominators require original verification · Cold, heat and simulated-altitude experiments
Measures: Physical and mental task performance. Historical controls and repeated testing; not a single uniform trial or proof of operational protection.
The Kirov departmental history places B-100/B-200/B-300 within its antihypoxant and meteoadaptation program. It describes state-dependent effects: rested participants and fatigued participants did not respond alike. This is an originating-department account, not independent replication.
The 2012 transcription lists Bemitil 300 mg, Trekrezan 100 mg, nicotinic acid 30 mg and riboflavin 5 mg. B-100/B-200 varied the Bemitil quantity. These are historical formulation details, not preparation or dosing instructions.
Mental fatigue
After intensive educational workload, 30 participants received B-300 and 10 placebo. Cognitive and wellbeing measures favored treatment.
Activation and accuracy
The separate 34-person escalation experiment used 12/12/10 groups. Higher exposure increased errors despite subjective activation; feeling more active did not mean greater precision.
Environmental chambers
Cold, heat and simulated altitude were studied separately. Historical baseline controls, small groups and repeated testing limit interpretation. The negative antihypoxia passage concerns Trekrezan, before the B-300 results.
Laboratory performance is not proof of safe watchkeeping, rescue work or protection from hazardous exposure. Component research cannot establish combination synergy. The retrospective clinical-use references do not identify a B-300-specific controlled trial in brain injury or intoxication.
A later three-ingredient proposal is reported with different vitamin content. The original portfolio, ownership, patent status and registration need verification; it is not assumed equivalent to the experimental formulation.
Educational only; not medical advice. Seek qualified healthcare help for any medical condition. Experimental formulations are not personal treatment recommendations.
2012 · Development and study of antihypoxant-based psychoenergizing formulations for human physical and mental performanceMental-fatigue experiment: 30 active versus 10 placebo
2012Human comparative studyRussian source · see review scope